Sartorius Overview
- Year Founded
-
1870
- Status
-
Public
- Employees
-
14,273
- Stock Symbol
-
SRT
- Investments
-
27
- Share Price
-
$249.17
- (As of Friday Closing)
Sartorius General Information
Description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact Information
Website
www.sartorius.comCorporate Office
- Otto-Brenner-Strasse 20
- 37079 Goettingen
- Germany
Corporate Office
- Otto-Brenner-Strasse 20
- 37079 Goettingen
- Germany
Sartorius Stock Performance
As of 13-Nov-2026, Sartorius’s stock price is $249.17. Its current market cap is $19.7B with 69.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $249.17 | $251.30 | $182.87 - $264.96 | $19.7B | 69.1M | 3.6K | $3.67 |
Sartorius Financials Summary
As of 30-Sep-2026, Sartorius has a trailing 12-month revenue of $4.26B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 23,818,601 | 23,692,687 | 19,203,708 | 28,962,731 |
| Revenue | 4,257,979 | 3,990,999 | 3,658,252 | 3,674,404 |
| EBITDA | 1,172,896 | 1,034,946 | 827,481 | 939,891 |
| Net Income | 201,815 | 174,728 | 90,896 | 222,475 |
| Total Assets | 10,968,678 | 11,414,006 | 10,512,898 | 10,772,675 |
| Total Debt | 4,434,692 | 5,030,305 | 4,744,800 | 5,871,110 |
Sartorius Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sartorius Comparisons
Industry
Financing
Details
Sartorius Competitors (10)
One of Sartorius’s 10 competitors is Bruker, a Formerly VC-backed company based in Billerica, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bruker | Formerly VC-backed | Billerica, MA | ||||
| GE HealthCare Technologies | Corporation | Chicago, IL | ||||
| Tecan Trading | Corporation | Mannedorf, Switzerland | ||||
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Abbott India | Corporation | Mumbai, India |
Sartorius Patents
Sartorius Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| DE-102025125599-B3 | Scale | Active | 01-Jul-2025 | ||
| US-20260339088-A1 | Enclosed confocal optical system | Pending | 23-Apr-2025 | ||
| WO-2026226628-A1 | Enclosed confocal optical system | Pending | 23-Apr-2025 | ||
| US-20260339085-A1 | Moveable confocal optical module | Pending | 23-Apr-2025 | ||
| WO-2026226624-A1 | Moveable confocal optical module | Pending | 23-Apr-2025 |
Sartorius Signals
Sartorius Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sartorius Investments & Acquisitions (27)
Sartorius’s most recent deal was a Corporate with SPARTA Biodiscovery for . The deal was made on 16-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SPARTA Biodiscovery | 16-Jul-2025 | Corporate | Other Commercial Products | ||
| MatTek | 01-Jul-2025 | Merger/Acquisition | Biotechnology | ||
| Visikol | 04-Apr-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| TheWell Bioscience | 19-Apr-2024 | Corporate | Biotechnology | ||
| Sartorius Stedim Biotech | 07-Feb-2024 | PIPE | Other Pharmaceuticals and Biotechnology |
Sartorius ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
19.64 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Sartorius Exits (2)
Sartorius’s most recent exit was on 14-Dec-2020 from Curexsys. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Curexsys | 14-Dec-2020 | Completed |
|
||
| LabTwin | 28-Mar-2019 | Early Stage VC | Completed |
|
Sartorius Affiliates
Subsidiaries (25)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sartorius Nordic Oy | Fi Helsinki, Finland | 2020 | |
| Sartorius Stedim Chromatography Resins | Cergy, France | 2019 | |
| Sartorius Stedim Chromatography Systems | Royston, United Kingdom | 2019 | |
| Sartorius Bioanalytical Instruments | Bohemia, NY | 2019 | |
| Sartorius Ventures | Gottingen, Germany | 2018 |
Sartorius FAQs
-
When was Sartorius founded?
Sartorius was founded in 1870.
-
Where is Sartorius headquartered?
Sartorius is headquartered in Goettingen, Germany.
-
What is the size of Sartorius?
Sartorius has 14,273 total employees.
-
What industry is Sartorius in?
Sartorius’s primary industry is Diagnostic Equipment.
-
Is Sartorius a private or public company?
Sartorius is a Public company.
-
What is Sartorius’s stock symbol?
The ticker symbol for Sartorius is SRT.
-
What is the current stock price of Sartorius?
As of 13-Nov-2026 the stock price of Sartorius is $249.17.
-
What is the current market cap of Sartorius?
The current market capitalization of Sartorius is $19.7B.
-
What is Sartorius’s current revenue?
The trailing twelve month revenue for Sartorius is $4.26B.
-
Who are Sartorius’s competitors?
Bruker, GE HealthCare Technologies, Tecan Trading, Bio-Rad Laboratories, and Abbott India are some of the 10 competitors of Sartorius.
-
What is Sartorius’s annual earnings per share (EPS)?
Sartorius’s EPS for 12 months was $3.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process